The Type 1 Diabetes market report from DelveInsight provides an in-depth understanding of Type 1 Diabetes, historical and forecasted epidemiology, and Type 1 Diabetes market trends in the 7MM. The report also examines current Type 1 Diabetes treatment practices/algorithms, market drivers, market constraints, and unmet medical needs in order to identify and evaluate the market’s underlying potential.
Some of the Important findings from the Type 1 Diabetes Market Report
According to the National Diabetes Statistics Report (2020), the United States has 34.2 million people with diabetes in 2018, accounting for 10.5 percent of the total population.
In 2018, 210,000 children and adolescents under the age of 20 in the United States were found to be diabetic, of which 187,000 peoplehad Type 1 Diabetes diagnosis (National Diabetes Statistics Report, 2020).
Rosenbauer et al. (2019) study showed that males had a greater Type 1 Diabetes prevalence over females in a group of patients over the age of 18.
Key Type 1 Diabetes pipelines therapies include Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed) and several others.
Several pharmaceutical companies such as Provention Bio, Tolerion, Dompe Pharmaceutical, ActoBiotics, Oramed and others are developing novel products for Type 1 Diabetes treatment.
For further information, request sample @ Type 1 Diabetes Management
The Type 1 Diabetes market report covers current treatment practices, new pharmaceuticals, individual therapy market share, and present and predicted Type 1 Diabetes market size from 2018 to 2030, segmented by seven major markets.
Type 1 Diabetes: Overview
Diabetes is a long-term metabolic disease marked by high or low blood glucose (or blood sugar) levels, which can cause considerable damage to the heart, blood vessels, eyes, kidneys, and nerves. Type 1 Diabetes (TD-1), Type 1 Diabetes (TD2), and Gestational Diabetes are the three kinds of diabetes classified clinically.
Type 1 Diabetes is an autoimmune condition that affects the body’s immune system. It is the most prevalent type of diabetes in children, but it can strike anyone at any age. The common Type 1 Diabetes symptoms include excessive thirst, impaired vision, dry mouth, upset stomach and vomiting, bedwetting, frequent urination, unexplained weight loss, exhaustion, difficulty breathing, lack of energy, and persistent hunger.
Type 1 Diabetes Epidemiology Segmentation
Type 1 Diabetes Total Prevalent Cases
Type 1 Diabetes Total Diagnosed Prevalent Cases
Type 1 Diabetes Total Gender-Specific Prevalent Diagnosed Cases
Type 1 Diabetes Total Age-Specific Prevalent Diagnosed Cases
Type 1 Diabetes Treated Cases
Type 1 Diabetes Treatment Landscape
People with Type 1 Diabetes must follow a different plan. A treatment plan, also known as a diabetes management plan, assists people in managing their diabetes while remaining healthy and active. Everyone’s plan is different, and it is based on a person’s health needs as well as the recommendations of the diabetes health care team. The treatment’s goal is to keep your blood sugar levels as close to normal as possible in order to delay or prevent complications.
Forxiga (dapagliflozin) and sotagliflozin (sold as Zynquista) are EMA approved Type 1 Diabetes drugs used for treating the patients with Type 1 Diabetes.
Type 1 Diabetes Market
Owing to the rising prevalence and the projected launch of new therapies such as Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed) and others, the Type 1 Diabetes market is predicted to rise during the forecast period, 2021–2030.
Get an overview about diabetes @ Type 1 Diabetes Market Size
Type 1 Diabetes Pipeline Therapies and Key Players
Teplizumab: Provention Bio
TOL-3021: Tolerion
Ladarixin: Dompe Pharmaceutical
AG019: ActoBiotics
ORMD-0801: Oramed
Type 1 Diabetes Market Drivers
Rise in Insulin consumption as the number of diabetic patients increases
Increase in R&D
Uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs
Type 1 Diabetes Market Barriers
Entry of Biosimilars
High treatment and diagnosis Cost
Inadequate reimbursement policies
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
Type 1 Diabetes Key Companies: Provention Bio, Tolerion, Dompe Pharmaceutical, ActoBiotics, Oramed, among others.
Type 1 Diabetes Key Pipeline Therapies: Teplizumab (Provention Bio), TOL-3021 (Tolerion), Ladarixin (Dompe Pharmaceutical), AG019 (ActoBiotics), ORMD-0801 (Oramed), and others.
Type 1 Diabetes Segmentation: By Geography, By Type 1 Diabetes drugs
Analysis: Comparative and conjoint analysis of Type 1 Diabetes emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Report Introduction
2.
Executive Summary of Type 1 Diabetes
3.
SWOT Analysis of Type 1 Diabetes
4.
Type 1 Diabetes: Patient Share (%) Overview at a Glance
5.
Type 1 Diabetes: Market Overview (%) at a Glance
6.
Type 1 Diabetes Disease Background and Overview
7.
Type 1 Diabetes Epidemiology and Patient Population
8.
Country-Specific Patient Population of Type 1 Diabetes
9.
Type 1 Diabetes Current Treatment and Medical Practices
10
Type 1 Diabetes Patient Journey
.11.
Type 1 Diabetes Unmet Needs
12.
Type 1 Diabetes Key Endpoint of Clinical Trials
13.
Type 1 Diabetes Marketed Products
14.
Type 1 Diabetes Emerging Therapies
15.
Conjoint Analysis of Type 1 Diabetes Therapies
16.
Type 1 Diabetes: Market Size of 7MM
17.
Type 1 Diabetes Country-Wise Market Analysis (2018 –2030)
18.
Type 1 Diabetes Market Access and Reimbursement
19.
Type 1 Diabetes Market drivers
20.
Type 1 Diabetes Market barriers
21.
Appendix
22.
DelveInsight Capabilities
23.
Disclaimer
24.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Related Reports
Dementia with Diabetes Market
Get comprehensive historical and forecast analysis of Dementia with Diabetes Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as vTv Therapeutics, Novo Nordisk, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/